Novo Nordisk(Ozempic) Crash: The Fall of the Obesity King ($50B Wiped Out)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
$50 BILLION DOLLARS. Gone. In a single trading session.
Yesterday, Novo Nordisk—the company behind Ozempic and Wegovy, the company that basically invented the weight loss drug revolution—watched 18% of its market value disappear in hours.
But here's what makes this story wild. After the crash, their new CEO got in front of investors and said: "People should expect that it goes down before it comes back up."
He told them it gets worse from here.
Today's Show:
- The Crash: $50B wiped out, 18% drop, guidance 10x worse than expected
- The Trump Factor: TrumpRx forced an 85% price cut on Wegovy
- The Competition: Eli Lilly's next-gen drug showing 28.7% weight loss
- The Knockoffs: Compounding pharmacies selling semaglutide for $200 vs $1,000
- The Leadership Shakeup: New CEO, US chief leaving, former CEO back as chairman
- The Denmark Problem: One company = 40% of the Copenhagen Stock Exchange
- Bull vs Bear Case: Volume play or falling knife?
Key Numbers:
- Stock drop: 18% in one day
- 2025 performance: Down 50%
- Guidance: Sales DOWN 5-13% (analysts expected -1.4%)
- Wegovy pill signups: 170,000 in first 4 weeks
- Price cut: $1,000/month → $149/month (85% reduction)
- Eli Lilly next-gen results: 28.7% average weight loss
Sources Referenced:
- CNBC: Novo Nordisk Stock Crashes on 2026 Guidance
- Reuters: Novo Nordisk Issues Bleak 2026 Forecast
- Reuters: Trump Obesity Drug Deal with Novo and Lilly
- Reuters: Lilly's Next-Gen Drug Tops Zepbound in Trials
- Yahoo Finance: Novo Nordisk Shares Tumble 18%
- Euronews: Novo Nordisk Stock Sinks After Bleak Forecast
CEO Quotes (Mike Doustdar):
- "People should expect that it goes down before it comes back up"
- "No matter how well the pill does, the price hit on the existing business trumps the great pill launch"
- "We are creating affordability for millions of patients who simply could not afford it"
Chapters:
- 00:00 - The $50 Billion Crash
- 01:15 - What Is Novo Nordisk?
- 02:30 - The Catastrophic 2026 Guidance
- 03:45 - CEO Says "It Gets Worse"
- 05:00 - The Trump Factor: 85% Price Cut
- 06:30 - Eli Lilly Is Winning
- 08:00 - Compounding Pharmacies
- 09:00 - Leadership Shakeup
- 10:00 - The Denmark Problem
- 11:00 - What Analysts Are Saying
- 12:00 - Bull Case vs Bear Case
- 14:30 - What To Watch
- 15:45 - Final Thoughts
Follow the Show:
Website: moneymen.fm
Tools We Use:
→ TradingView: Get TradingView (Charts & analysis - affiliate link)
- (00:00) - The $50 Billion Crash
- (01:15) - What Is Novo Nordisk?
- (02:30) - The Catastrophic 2026 Guidance
- (03:45) - CEO Says It Gets Worse
- (05:00) - The Trump Factor: 85% Price Cut
- (06:30) - Eli Lilly Is Winning
- (08:00) - Compounding Pharmacies
- (09:00) - Leadership Shakeup
- (10:00) - The Denmark Problem
- (11:00) - What Analysts Are Saying
- (12:00) - Bull Case vs Bear Case
- (14:30) - What To Watch
- (15:45) - Final Thoughts
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.